ArticleTranslational cancer research2025
Identification of cancer-associated fibroblast subpopulation and construction of an immunotherapy signature for gastric cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A stromal-derived five-gene signature predicts gastric cancer recurrence through integrated bioinformatics and single-cell analysis.Translational cancer research · 2026Article
- The impact of ulinastatin on postoperative clinical outcomes in patients with gastric cancer: a retrospective cohort analysis.Journal of gastrointestinal oncology · 2026Article
- ECM remodeling-associated immune signatures and hub proteins: predictive markers and therapeutic targets for metastatic gastric cancer.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer-associated fibroblasts (CAFs) are thought to contribute to malignant tumor progression. Although it has been reported that signatures based on CAFs-specific genes could be used to evaluate the prognosis of gastric cancer (GC), as a heterogeneous subgroup, the CAFs subpopulations and their characteristics in the GC microenvironment were still ambiguous. This study aimed to identify CAFs subgroups in GC and evaluate their prognostic and immunotherapy relevance. Methods: We utilized the Gene Expression Omnibus (GEO) database to acquire single-cell sequencing data of CAFs associated with GC, and The Cancer Genome Atlas (TCGA) database to obtain GC patient messenger RNA (mRNA) expression profiles. All CAFs were classified using unsupervised clustering based on the expression of 235 characteristic genes. The unsupervised clustering results indicated that the CAFs in the GC microenvironment were divided into four clusters. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis revealed the intrinsic differences of these clusters and the CIBERSORT algorithm was used to perform immune cell infiltration analysis. Results: Cluster1, Cluster2 and Cluster4 were partly related to extracellular matrix production, while Cluster3 was mainly related to the TGF-β pathway. In addition, the CAF-related score based on Cluster3 (CRS3) could significantly distinguish the prognosis of patients. Moreover, patients with low CRS3 scores had a higher tumor mutation burden and higher levels of immune checkpoints (CTLA-4, LAG3, MAGE-A3, PD-1 and PD-L1), which might indicate a higher immunotherapy response. Conclusions: All in all, our study revealed four heterogeneous subpopulations of CAFs in the GC microenvironment, and highlighted that Cluster3 was associated with prognosis and response to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.